Compare VET & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VET | SNDX |
|---|---|---|
| Founded | 1994 | 2005 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.8B |
| IPO Year | 2004 | 2014 |
| Metric | VET | SNDX |
|---|---|---|
| Price | $13.94 | $24.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 12 |
| Target Price | $15.00 | ★ $84.17 |
| AVG Volume (30 Days) | ★ 2.5M | 1.2M |
| Earning Date | 03-04-2026 | 05-04-2026 |
| Dividend Yield | ★ 2.65% | N/A |
| EPS Growth | N/A | ★ 11.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $172,352,000.00 |
| Revenue This Year | $15.13 | $112.05 |
| Revenue Next Year | N/A | $51.24 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 627.84 |
| 52 Week Low | $5.14 | $8.59 |
| 52 Week High | $14.70 | $25.16 |
| Indicator | VET | SNDX |
|---|---|---|
| Relative Strength Index (RSI) | 76.67 | 64.15 |
| Support Level | $7.42 | $19.46 |
| Resistance Level | N/A | $25.16 |
| Average True Range (ATR) | 0.62 | 1.12 |
| MACD | 0.22 | 0.09 |
| Stochastic Oscillator | 77.31 | 67.57 |
Vermilion Energy Inc is an international oil and gas-producing company. The company engages in full-cycle exploration and production programs that focus on the acquisition, exploration, development, and optimization of producing properties in North America, Europe, and Australia. The majority of Vermilion's revenue is derived from the production and sale of petroleum and natural gas. In each market, the company relies on a host of drilling and well-completion techniques to keep production at attractive levels. Geographically, the company derives majority of its revenue from Canada.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.